Dr. Andtbacka on Optimal Use of T-VEC in Melanoma

Video

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the optimal use of talimogene laherparepvec (T-VEC) in patients with melanoma.

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the optimal use of talimogene laherparepvec (T-VEC; Imlygic) in patients with melanoma.

As reported in the OPTiM study, the trial that led to the FDA approval of T-VEC, the agent was found to elicit more responses in the population of patients with regional disease. This is an underserved area, Andtbacka explains, as several clinical trials do not include patients with this disease stage.

This demonstrates that oncolytic immunotherapy agents, such as T-VEC, are effective in these patients. However, it should be recognized that other checkpoint inhibitors also have activity in this population, although there has never been a head-to-head comparison of them to T-VEC, he adds.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,